-
-
The second-generation of drug-eluting stent (DES) technology is now reality in the U.S. Medtronic (Minneapolis) in early February reported FDA approval of the Endeavor DES, making it the first in the DES 2.0 family of these devices to win marketing okay in the U.S.
-
Cytori Therapeutics (San Diego) reported enrollment of the first two patients in a clinical trial using adipose-derived stem and regenerative cells in the treatment of heart attack using its device/cell treatment combination system.
-
NMT Medical (Boston) in late January said it was closing its PFO/migraine trial, MIST II, citing "challenges" in patient enrollment.
-
In an effort to better understand cardiac and other illnesses, researchers from the Université de Montréal (UdeM) said they have used a supercomputer to conduct what they believe is the largest mathematical simulation of the electrical activity of a human heart a 2-billion-element model.
-
After receiving a non-substantially equivalent letter from the FDA last month for its skin cholesterol test, Prevu, PreMD (Toronto) has now filed a request for a second level review of the 510(k) submission. "It's been devastating in terms of impact on the company," Brent Norton, president/CEO told Cardiovascular Devices & Drugs, later acknowledging that the decision puts the company in "a tough spot."
-
England's influential National Institute for Health and Clinical Excellence (NICE) has reversed its earlier position opposing use of drug-eluting stents (DES), clearing the way for reimbursement of such interventions in what is estimated to be a $100 million market. If there are no appeals against the draft decision, the final guidance on DES will go into effect in March.
-
Acacia Research; Acacia Patent Acquisition; Acrongenomics; Molecular Vision; Angiotech Pharmaceuticals; Symphony Medical; Boston Scientific; Getinge Group; Bristol-Myers Squibb; Bristol-Myers Squibb Medical Imaging; Micrus Endovascular; Genesis Medical Interventional; NewCardio; Marine Park Holdings; Synovis Life Technologies; Heraeus Vadnais
-
As if a huge debt, a sagging share price, weakened sales and a variety of regulatory problems arent enough, a jury has ordered Boston Scientific (Natick, Massachusetts) to pay $431 million in damages to Dr. Bruce Saffran, a New Jersey radiologist who charged that the medical device maker's drug-eluting stents (DES) infringe a patent that he received in 1997.
-
Amic; Arbor Surgical Technologies; Medtronic; CV Therapeutics; Medlogics Device; St. Jude Medical; HealthTrust Purchasing Group; Masimo
